Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with metformin
Background: Metformin is considered the gold standard for type 2 diabetes treatment as monotherapy and in combination with sulphonylureas and insulin, whereas the combination of metformin with thiazolidinediones is relatively less studied. The aim of the present study was to assess the differential effect on glycaemic metabolism and lipid variables of the combination of metformin plus pioglitazone or metformin plus rosiglitazone in diabetic patients with metabolic syndrome.
No Supplementary Data
No Article Media
Document Type: Research Article
Affiliations: ‘G. Descovich’ Atherosclerosis Study Center, ‘D. Campanacci’ Clinical Medicine and Applied Biotechnology Department, University of Bologna, Bologna, Italy
Publication date: 2007-02-01